title: Do We Need a New Definition of Hypertension After SPRINT?
authors.affiliation: Lady Davis Institute for Medical Research, and Department of Medicine, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada; ernesto.schiffrin@mcgill.ca.
authors.forename: Ernesto L
authors.initials: EL
authors.lastname: Schiffrin
authors.affiliation: Vascular Biology and Hypertension Program, University of Alabama at Birmingham, Birmingham, Alabama, USA;
authors.forename: David A
authors.initials: DA
authors.lastname: Calhoun
authors.affiliation: Division of General Medicine, Hypertension Section, Department of Medicine, Southern Illinois University School of Medicine, Springfield, Illinois, USA.
authors.forename: John M
authors.initials: JM
authors.lastname: Flack
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000453:epidemiology; D003327:Coronary Disease / Q000453:epidemiology*; D006801:Humans; D006973:Hypertension / Q000145:classification / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology; D010347:Patient Care Planning; D058246:Prehypertension / Q000145:classification / Q000175:diagnosis* / Q000453:epidemiology; D016032:Randomized Controlled Trials as Topic; D040242:Risk Reduction Behavior; D020521:Stroke / Q000453:epidemiology*
chemical_list: D000959:Antihypertensive Agents